Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs. Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Glucagon), combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development. In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.
Show more
Lyon-3E-Arrondissement, FR
Size (employees)
130 (est)+10%
Adocia was founded in 2005 and is headquartered in Lyon-3E-Arrondissement, FR
Report incorrect company information

Adocia Office Locations

Adocia has an office in Lyon-3E-Arrondissement
Lyon-3E-Arrondissement, FR (HQ)
115 Avenue Lacassagne
Show all (1)
Report incorrect company information

Adocia Financials and Metrics

Adocia Financials

Market capitalization (31-Oct-2017)

109.6 m

Closing share price (31-Oct-2017)

Adocia's current market capitalization is €109.6 m.
Show all financial metrics
Report incorrect company information